Professor and HOD of Pulmonary Medicine, SVS Medical College and Sr. Consultant Pulmonologist, Kunal Institute of Medical Specialities Pvt. Ltd, Hyderabad and Apollo Hospitals, Hyderabad, India
*Corresponding Author: Pradyut Waghray, Professor and HOD of Pulmonary Medicine, SVS Medical College and Sr. Consultant Pulmonologist, Kunal Institute of Medical Specialities Pvt. Ltd, Hyderabad and Apollo Hospitals, Hyderabad, India.
Received: June 18, 2020; Published: July 16, 2020
The burden of Covid 19 is increasing all over the world. Pidotimod, an Immunomodulator had been used in COPD patients to prevent the exacerbations of COPD and also in the prevention of Recurrent respiratory tract infections both in adults and children successfully. A recent study indicates that the number of COPD cases in India increased from 28.1 million in 1990 to 55.3 million in 2016 [1,2]. The correlation between immune dysfunction and chronic respiratory diseases such as COPD is well established. COPD is characterized by chronic inflammation of the airway which compromises innate as well as adaptive immune responses.
Citation: Pradyut Waghray. “Emerging Landscape in the Management of Covid 19. Role of Pidotimod".Acta Scientific Nutritional Health 4.8 (2020): 33-34.
Copyright: © 2020 Pradyut Waghray. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.